Two union funds are suing Novartis, claiming that the Swiss drugmaker used "sham" patent-infringement claims to delay a generic version of its blockbuster leukemia drug Gleevec. Though just the latest in a series of legal battles over drug patent settlements, it's the first attempt by purchasers to block one of those settlements, the plaintiffs' lawyers said.
The good news for Allergan's ex-headquarters in Irvine, CA: CEO Brent Saunders says the operations there are still key to the company. More good news: The layoffs that hit that site are now over and done, he says.
A U.S. judge refused to toss out lawsuits claiming that Eli Lilly & Co. downplayed withdrawal symptoms associated with its blockbuster antidepressant Cymbalta. As Bloomberg reports, Lilly will now have to fight claims that it misled consumers about "brain zaps" and other side effects suffered by people trying to quit using the drug.
Eli Lilly scored a victory in its patent battle for lung cancer blockbuster Alimta in Europe, as the Court of Appeal in London ruled against Actavis' plan to market copycat versions of the med.
The CDC's Advisory Committee for Immunization Practices gave the go-ahead for wider use of meningitis B vaccines, but stopped short of a universal recommendation, not the result many--including GlaxoSmithKline and Pfizer--were hoping to see.
AbbVie knows it has to press its case for Viekira Pak if it's going to get--and keep--a sizable share of the hepatitis C market. Today, it unveiled some new data that could help it do just that.
Former Allergan Chairman and CEO David Pyott found himself out of a job when Actavis snapped up his company. He walked away with quite a golden parachute, however--$534 million, says the Orange County Register--and now he has another $5 million to add to his balance sheet.
If you've spent any time reading biopharma's securities filings, you've noticed the litany of potential problems every company discloses--everything from natural disasters and terrorist attacks to patent lawsuits and regulatory setbacks.
What's in the water at AstraZeneca? Maybe it's an elixir for top managers who want to run a smaller drugmaker. Maybe it's an anti-Big Pharma potion. Either way, it means a second high-level exec has left the U.K.-based drugmaker for a CEO post elsewhere.
The top 10 companies producing diabetes meds raked in about $62 billion in global sales in 2014, up 5.1% from the previous year, according to a report from data analytics firm GlobalData. Companies such as Novo Nordisk, Sanofi and Merck lead the pack, posting solid gains for their products as they compete for a piece of a rapidly growing market.
The game is on at Hospira's massive new manufacturing plant in India. After two delays to work out kinks identified by the FDA, the drugmaker says the agency has signed off on it and Hospira has started "limited commercial production at the facility."
Mylan is sending its CFO, John Sheehan, on the road in Israel.
The American Society of Clinical Oncology promised a rating scale for cancer drugs--and now, it has delivered. Let the blowback begin.
China's hit-and-miss government oversight poses special challenges for drug regulators who too often find companies there skirting the standards they expect. For the second time this year, European regulators have put a halt on exports from a Chinese company that they discovered had serious problems.
Growth in emerging markets may be slowing, but pharma sales there are still outpacing those everywhere else. And if recent numbers are any indication, AstraZeneca is topping its rivals for emerging markets expansion.
The Medicines Co. has suffered a series of setbacks since it kicked off late-stage studies for its blood-thinning injection cangrelor almost a decade ago. But now, the company is enjoying a bright point as the FDA signed off on the drug for a smaller subset of patients, giving Medicines Co. a boost as it braces for generic competition for one of its bestsellers.
The cost-effectiveness watchdogs at the National Institute for Health and Care Excellence have put their money behind biosimilars. Remicade biosimilars, to be exact, in new guidance for treating rheumatoid arthritis.
A group of investment funds has teamed up to buy generics maker Alvogen. A consortium led by CVC Capital Partners snapped up a majority stake in the NJ-based company, in a deal valuing Alvogen at $2 billion.
Pharma ad budgets may be set to dip overall in 2016, but the industry's big spenders will still be shelling out $2 billion each--or more--to promote their drugs, according to an annual spending study.
Early on in the cancer drug pricing debates, doctors at Memorial Sloan Kettering Cancer Center made waves by rejecting a new Sanofi colon cancer drug as too expensive for its benefits. Now, the noted hospital has taken its cost-benefit analysis to more than 50 cancer meds.